Bacteria in the treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 6, 2004, Pages 629-639

  Lin, John ^a   Lin, Eugene ^a   Nemunaitis, John ^a  

^a Mary Crowley Medical Research Center   (United States)

Author keywords

Bacteria; Cancer; Gene delivery

Indexed keywords

AMPICILLIN; BCG VACCINE; CANCER VACCINE; CANVAXIN; CARCINOEMBRYONIC ANTIGEN; CD18 ANTIGEN; CD40 LIGAND; COMBRETASTATIN A4 PHOSPHATE; CYTOSINE DEAMINASE; DNA VACCINE; ENTEROTOXIN; FLUOROURACIL; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 14; INTERLEUKIN 18; INTERLEUKIN 2; MELAN A; MITOMYCIN C; NITROREDUCTASE; ONCOVAX CL; RECA PROTEIN; RECOMBINANT GAMMA INTERFERON; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; BLADDER CANCER; CANCER REGRESSION; CANCER THERAPY; CHILL; CLINICAL TRIAL; CLOSTRIDIUM ACETOBUTYLICUM; COLON CANCER; CORONARY ARTERY SPASM; ESCHERICHIA COLI; FEVER; GENE DELIVERY SYSTEM; GENE MUTATION; GENE VECTOR; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; INSOMNIA; LISTERIA; LYMPHADENITIS; MELANOMA; MUSCLE WEAKNESS; MYCOBACTERIUM BOVIS; NEUROBLASTOMA; NONHUMAN; PAIN; RECOMBINANT DNA TECHNOLOGY; REVIEW; SALMONELLA TYPHIMURIUM; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR NECROSIS; VOMITING;

ANIMALS; BACTERIAL INFECTIONS; DNA, BACTERIAL; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

BACTERIA (MICROORGANISMS);

EID: 11344266454     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Nauts HC: The beneficial effects of bacterial infections on host resistance to cancer: End result in 449 cases. In: Cancer Research Institute Monograph No 8, 2nd Edition. New York, NY, USA (1980).
2. Nauts HC, McLaren JR: Coley toxins - the first century. Adv Exp Med Biol (1990) 267:483-500.
3. Schlechte H, Elbe B: Recombinant plasmid DNA variation of Clostridium oncolyticum - model experiments of cancerostatic gene transfer. Zentralbl Bakteriol Mikrobiol Hyg (1988) 268 3):347-356.
4. Parker RC, Plummber CC, Siebenmann CO, Chapmann MG: Effect of histolyticus infections and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med (1947) 66:461-465.
5. Malmgren RA, Flanigan CC: Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res (1955) 15(7):473-478.
6. Mose JR, Mose G: Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich Tumor des Maus. Z Krebsforsch (1959) 63:63-74.
7. Carey RW, Holland JF, Whang HY, Neter E, Bryant B: Clostridial oncolysis in man. Eur J Cancer (1967) 3:37-46.
8. Mose JR, Mose G: Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res (1964) 24 212-216.
9. Heppner F, Mose JR: The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir (Wien) (1978) 42(1-2):123-125.
10. Mose JR: Experiments to improve the oncolysis-effect of clostridial-strain M55 (author's transl). Zentralbl Bakteriol (1979) 244(4):541-545.
11. Thiele EH, Arison RN, Boxer GE: Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res (1964) 2:222-233.
12. Gericke D, Dietzel F, Ruster I: Further progress with oncolysis due to local high frequency hyperthermia, local x-irradiation and apathogenic clostridia. J Microw Power (1979) 14 2):163-166.
13. Schlechte H, Schwabe K, Mehnert WH, Schulze B, Brauniger H: Chemotherapy for tumours using clostridial oncolysis, antibiotics and cyclophosphamide: Model trial on the UVT 15264 tumour. Arch Geschwulstforsch (1982) 52(1):41-48.
14. Lambin P, Theys J, Landuyt W, Rijken P, van der Kogel A, van der Schueren E, Hodgkiss R, Fowler J, Nuyts S, de Bruijn E et al: Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumors. Anaerobe (1998) 4 4):183-188.
15. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther (1997) 4(8):791-796.
16. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 57 10):1829-1834.
17. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res (1999) 19(1A):189-195.
18. Horsman MR, Ehmrooth E, Ladekarl M, Overgaard J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys (1998) 42(4):895-898.
19. Theys J, Landuyt W, Nuyts S, Van Mellaert L, Bosmans E, Rijnders A, Van Den Bogaert W, van Oosterom A, Anne J, Lambin P: Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol (2001) 30 1):37-41.
20. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B: Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA (2001) 98(26 ):15155-15160.
21. Alexandroff AB, Jackson AM, O'Donnell MA, James K: BCG immunotherapy of bladder cancer: 20 Years on. Lancet (1999) 353(9165):1689-1694.
22. Bohle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer. A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol (2003) 169(1):90-95.
23. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol (2002 168 5):1964-1970.
24. Theys J, Barbe S, Landuyt W, Nuyts S, Van Mellaert L, Wouters B, Anne J, Lambin P: Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther (2003) 3(3 ):207-221.
25. Dietrich G, Spreng S, Favre D, Viret JF, Guzman CA: Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr Opin Mol Ther (2003) 5(1):10-19.
26. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP: Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood (1998) 92(9):3172-3176.
27. Darji A, zur Lage S, Garbe AI, Chakraborty T, Weiss S: Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol (2000) 27 4):341-349.
28. Weiss S, Krusch S: Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells. Biol Chem (2001) 382(4):533-541.
29. Lin E, Nemunaitis J: Oncolytic viral therapies. Cancer Gene Ther (2004) 11(10):643-664.
30. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST: Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med (2003) 9(5):533-539.
31. Aron-Maor A, Shoenfeld Y: BCG immunisation and the 'Trojan horse' phenomenon of vaccination. Clin Rheumatol (2003) 22 1):6-7.
32. Dietrich G, Viret JF, Hess J: Novel vaccination strategies based on recombinant Mycobacterium bovis BCG. Int J Med Microbiol (2003) 292(7-8):441-451.
33. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL: Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer (2002) 102(6):629-637.
34. Tvinnereim AR, Hamilton SE, Harty JT: CDS+-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection. Infect Immun (2002) 70(1):153-162.
35. Pan ZK, Weiskirch LM, Paterson Y: Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res (1999) 59(20 ):5264-5269.
36. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF: Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol (1997) 71(11):8467-8474.
37. Vindurampulle CJ, Attridge SR: Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines. Infect Immun (2003) 71(1):287-297.
38. Yan ZX, Meyer TF: Mixed population approach for vaccination with live recombinant Salmonella strains. J Biotechnol (1996) 44(1-3):197-201.
39. Cardenas L, Dasgupta U, Clements JD: Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine (1994) 12 9):833-840.
40. Chatfield S, Roberts M, Londono P, Cropley I, Douce G, Dougan G: The development of oral vaccines based on live attenuated Salmonella strains. FEMS Immunol Med Microbiol (1993) 7 1):1-7.
41. Collins FM: Effect of adjuvant on immunogenicity of a heat-killed Salmonella vaccine. J Infect Dis (1972) 126 1):69-76.
42. Shata MT, Hone DM: Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T cells and antiviral protective immunity. J Virol (2001) 75(20):9665-9670.
43. Drabner B, Guzman CA: Elicitation of predictable immune responses by using live bacterial vectors. Biomol Eng (2001) 17(3):75-82.
44. Higgins DE, Shastri N, Portnoy DA: Delivery of protein to the cytosol of macrophages using Escherichia coli K-12. Mol Microbiol (1999) 31(6):1631-1641.
45. Radford KJ, Higgins DE, Pasquini S, Cheadle EJ, Carta L, Jackson AM, Lemoine NR, Vassaux G: A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: Application to cancer immunotherapy. Gene Ther (2002) 9(21):1455-1463.
46. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S: Oral somatic transgene vaccination using attenuated S. typhimurium. Cell (1997) 91 6):765-775.
47. Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ: Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun (2002) 70(4):1915-1923.
48. Brunham RC, Zhang D: Transgene as vaccine for Chlamydia. Am Heart J (1999) 138(5 Pt 2 ):S519-S522.
49. Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR: ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine (2000) 18(21 ):2193-2202.
50. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB: Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol (1999) 92(1):76-89.
51. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR: Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol (1999) 162 3):1603-1610.
52. Flo J, Tisminetzky S, Baralle F: Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent herpes simplex virus-2 induced disease in mice. Vaccine (2001) 19(13-14):1772-1782.
53. Elias F, Flo J: Modulation of the immune response mediated by oral transgene administration of IL-10. Cell Immunol (2002) 216(1-2):73-81.
54. Woo PC, Wong LP, Zheng BJ, Yuen KY: Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine (2001) 19 20-22):2945-2954.
55. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B: Oral immunization with HCV-NS3-transformed Salmonella: Induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology (2001) 121(5):1158-1166.
56. Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM: Mucosal and systemic HIV-1 Env-specific CD8+ T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine (2001) 20(3-4):623-629.
57. Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ: Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol Lett (2002) 82 3):197-204.
58. Xu F, Hong M, Ulmer JB: Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine (2003) 21(7-8):644-648.
59. Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM: Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine (2002) 20 15):1968-1974.
60. Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL: Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine (2001) 19(28-29):3947-3956.
61. Pawelek JM, Sodi S, Chakraborty AK, Platt JT, Miller S, Holden DW, Hensel M, Low KB: Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther (2002) 9 10):813-818.
62. Wilson RW, Ballantyne CM, Smith CW, Montgomery C, Bradley A, O'Brien WE, Beaudet AL: Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol (1993) 161(3 ):1571-1578.
63. Tjuvajev J, Blasberg R, Luo X, Zheng LM, King I, Bermudes D: Salmonella-based tumor-targeted cancer therapy: Tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J Control Release (2001) 74(1-3):313-315.
64. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M: Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 10(10):737-744.
65. Pawelek JM, Low KB, Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res (1997) 57(20):4537-4544.
66. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL et al: Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 17(1):37-41.
67. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J: Clostridium spores for tumor-specific drug delivery. Anticancer Drugs (2002) 13(2):115-125.
68. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H, Overgaard J: Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol (2000) 476:311-323.
69. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S: Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther (2000) 7(2):269-274.
70. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S: Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat (2001) 66(2):165-170.
71. Nakamura T, Sasaki T, Fujimori M, Yazawa K, Kano Y, Amano J, Taniguchi S: Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem (2002) 66 11):2362-2366.
72. Vazquez-Torres A, Jones-Carson J, Baumler AJ, Falkow, S, Valdivia R, Brown W, Le M, Berggren R, Parks WT, Fang FC: Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature (1999) 401(6755):804-808.
73. Uchiya K, Barbieri MA, Funato K, Shah AH, Stahl PD, Groisman EA: A Salmonella virulence protein that inhibits cellular trafficking. EMBO J (1999) 18(14):3924-3933.
74. Jain KK: Use of bacteria as anticancer agents. Expert Opin Biol Ther (2001) 1(2):291-300.
75. Pastan II, Kreitman RJ: Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev (1998) 31(1-2):53-88.
76. Kokai-Kun JF, McClane BA: Deletion analysis of the Clostridium perfringens enterotoxin. Infect Immun (1997) 65(3):1014-1022.
77. Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N: Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol (1997) 136(6):1239-1247.
78. McClane BA, McDonel JL: The effects of Clostridium perfringens enterotoxin on morphology, viability, and macromolecular synthesis in Vero cells. J Cell Physiol (1979) 99 2):191-200.
79. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol (2000) 74:181-273.
80. Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E: BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res (1984) 21:107-193.
81. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am (1992) 19 3):573-580.
82. Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM: Claudin-4: A new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology (2001) 121(3):678-684.
83. Minton NP: Clostridia in cancer therapy. Nat Rev Microbiol (2003) 1(3):237-242.
84. Li D, Mrsny RJ: Oncogenic Raf-1 disrupts epithelial tight junctions via downregulation of occludin. J Cell Biol (2000) 148(4):791-800.
85. Chen Y, Lu Q, Schneeberger EE, Goodenough DA: Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol Biol Cell (2000) 11 3):849-862.
86. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res (2000) 60(22):6281-6287.
87. Luelmo F: BCG vaccination. Am Rev Respir Dis (1982) 125(3 Pt 2):70-72.
88. Mastrangelo MJ, Baker AR, Katz HR: Cutaneous melanomain cancer in cancer. In: Principles and Practice in Oncology, 2nd Edition. DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (1985):1371-1442.
89. Morales A, Nickel JC: Immunotherapy for superficial bladder cancer. A developmental and clinical overview. Urol Clin North Am (1992) 19(3):549-556.
90. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg (1992) 216 4):463-482.
91. Haley JL, Young DG, Alexandroff A, James K, Jackson AM: Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α. Immunology (1999) 96 1):114-121.
92. Ratliff TL, Haaff EO, Catalona WJ: Interleukin-2 production during intravesical bacille Calmette-Guérin therapy for bladder cancer. Clin Immunol Immunopathol (1986) 40 2):375-379.
93. Fleischmann JD, Toossi Z, Ellner JJ, Wentworth DB, Ratliff TL, Imbembo AL: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. Cancer (1989) 64(7):1447-1454.
94. De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Van der Meijden AP, Vegt PD, Debruyne FM, Ruitenberg EJ: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 34(5):306-312.
95. Jackson AM, Prescott S, Hawkyard SJ, James K, Chisholm G: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol Immunother (1993) 36(1):25-30.
96. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD, James K: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol (1995) 99(3):369-375.
97. Alexandroff AB, Jackson AM, Skibinska A, James K: Production of IL-5, a classical Th 2 cytokine, following BCG immunotherapy of bladder cancer. Int J Oncol (1996) 9:179.
98. Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF: HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol (1989) 63(3):264-269.
99. Jackson AM, Alexandroff AB, McIntyre M, Esuvaranathan K, James K, Chisholm GD: Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol (1994) 47 4):309-312.
100. Yoneda M, Fukui Y, Yamanouchi T: Extracellular proteins of tubercle bacilli. V. Distribution of α and β antigens in various mycobacteria. Biken J (1965) 8(4):201-223.
101. Kuromatsu I, Matsuo K, Takamura S, Kim G, Takebe Y, Kawamura J, Yasutomi Y: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an α antigen from mycobacteria. Cancer Gene Ther (2001) 8(7):483-490.
102. Zheng LM, Luo X, Feng M, Li Z, Le T, Ittensohn M, Trailsmith M, Bermudes D, Lin SL, King IC: Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res (2000) 12(3):127-135.
103. Theys J, Landuyt W, Nuyts S, Van Mellaert L, van Oosterom A, Lambin P, Anne J: Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther (2001) 8(4):294-297.
104. Lee KC, Zheng LM, Margitich D, Almassian B, King I: Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent. Int J Toxicol (2001) 20 4):207-217.
105. King I, Bermudes D, Lin S, Belcourt M, Pike J, Troy K, Le T, Ittensohn M, Mao J, Lang W, Runyan JD et al: Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther (2002) 13(10):1225-1233.
106. Austin EA, Huber BE: A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol (1993) 43(3):380-387.
107. Liu SC, Minton NP, Giaccia AJ, Brown JM: Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther (2002) 9 4):291-296.
108. Deonarain MP, Spooner RA, Epenetos AA: Genetic delivery of enzymes for cancer therapy. Gene Ther (1995) 2(4 ):235-244.
109. Critchley RJ, Jezzard S, Radford KJ, Goussard S, Lemoine NR, Grillot-Courvalin C, Vassaux G: Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther (2004) 11(15):1224-1233.
110. Hahn H, Kaufmann SH: The role of cell-mediated immunity in bacterial infections. Rev Infect Dis (1981) 3 6):1221-1250.
111. Portnoy DA: Innate immunity to a facultative intracellular bacterial pathogen. Curr Opin Immunol (1992) 4(1 ):20-24.
112. Kaufmann SH, Hug E, Vath U, De Libero G: Specific lysis of Listeria monocytogenes-infected macrophages by class II-restricted L3T4+ T cells. Eur J Immunol (1987) 17(2):237-246.
113. Kaufmann SH: Possible role of helper and cytolytic T lymphocytes in antibacterial defense: Conclusions based on a murine model of listeriosis. Rev Infect Dis (1987) 9(Suppl 5):S650-S659.
114. Bishop DK, Hinrichs DJ: Adoptive transfer of immunity to Listeria monocytogenes. The influence of in vitro stimulation on lymphocyte subset requirements. J Immunol (1987) 139 6):2005-2009.
115. Harty JT, Pamer EG: CD8 T lymphocytes specific for the secreted p60 antigen protect against Listeris monocytogenes infection. J Immunol (1995) 154(9):4642-4650.
116. Harty JT, Bevan MJ: CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med (1992) 175(6):1531-1538.
117. Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, Brockstedt D, Hinrichs DJ, Higgins DE, Miller JF, Giedlin M, Bouwer HG: Listeria monocytogenes as a vaccine vector: Virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J Immunol (2004) 173(1):420-427.
118. Sewell DA, Douven D, Pan ZK, Rodriguez A, Paterson Y: Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg (2004) 130(1):92-97.
119. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD: Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: Further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology (1992) 76 2):286-291.
120. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD: Expression of adhesion molecules by bladder cancer cells: Modulation by interferon-γ and tumour necrosis factor-α. J Urol (1992) 148(5):1583-1586.
121. Campbell SC, Tanabe K, Alexander JP, Edinger M, Tubbs RR, Klein EA: Intercellular adhesion molecule-1 expression by bladder cancer cells: Functional effects. J Urol (1994) 151 5):1385-1390.
122. Finch PW, Chambers P, Emmerson PT: Identification of the Escherichia coli recN gene product as a major SOS protein. J Bacteriol (1985) 164(2):653-658.
123. Miller RV, Kokjohn TA: General microbiology of recA: Environmental and evolutionary significance. Annu Rev Microbiol (1990) 44:365-394.
124. Nuyts S, Theys J, Landuyt W, van Mellaert L, Lambin P, Anne J: Increasing specificity of anti-tumor therapy: Cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res(2001) 21(2A):857-861.
125. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anne J, Lambin P: Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation. Gene Ther (2001) 8(15):1197-1201.
126. Nuyts S, Van Mellaert L, Barbe S, Lammertyn E, Theys J, Landuyt W, Bosmans E, Lambin P, Anne J: Insertion or deletion of the Chao box modifies radiation inducibility of Clostridium promoters. Appl Environ Microbiol (2001) 67(10 ):4464-4470.
127. Soto LJ 3rd, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA: Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg (2003) 38(7):1075-1079.
128. Schadendorf D, Nestle FO: Autologous dendritic cells for treatment of advanced cancer - an update. Recent Results Cancer Res (2001) 158:236-248.
129. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4 3):328-332.
130. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ et al Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 6(3):332-336.
131. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM: Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother (2000) 23(4):487-498.
132. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB et al: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 190(11):1669-1678.
133. Iori F, Di Seri M, De Nunzio C, Leonardo C, Franco G, Spalletta B, Laurenti C: Long-term maintenance bacille Calmefte-Guérin therapy in high-grade superficial bladder cancer. Urology (2002) 59(3):414-418.
134. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN: Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-Year experience. Urology (2002) 59 2):227-231.
135. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM: Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: First randomized phase III trials show promise. Vaccine (2001) 19 17-19):2576-2582.
136. Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ: Live bacteria as the basis for immunotherapies against cancer. Expert Rev Vaccines (2002) 1(4):495-505.
137. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature (2001) 411(6835):380-384.
138. Berd D: Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine (2001) 19(17-19):2565-2570.
139. Geldmacher H, Taube C, Markert U, Kirsten DK: Nearly fatal complications of cervical lymphadenitis following BCG immunotherapy for superficial bladder cancer. Respiration (2001) 68 4):420-421.
140. Kamphuis JT, Buiting AG, Misere JF, van Berge Henegouwen DP, van Soolingen D, Rensma PL: BCG immunotherapy: Be cautious of granulomas. Disseminated BCG infection and mycotic aneurysm as late complications of intravesical BCG instillations. Neth J Med (2001) 68(2):71-75.
141. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ et al: Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 20(1):142-152.
142. Heimann DM, Rosenberg SA: Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J Immunother (2003) 26 2):179-180.
143. Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA: An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA (2000) 97(10):5492-5497.
144. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA: Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res (2001) 61(16):6178-6184.
145. Weth R, Christ O, Stevanovic S, Zoller M: Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther (2001) 8(8):599-611.
146. Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ: Oral DNA vaccination: Antigen uptake and presentation by dendritic cells elicits protective immunity. immunol Lett (2002) 80 2):89-96.
147. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA: Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol (2000) 35(6):641-646.
148. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA: Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood (2003) 101(2):649-654.
149. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, Dolman CS, Gillies SD, Reisfeld RA: A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol (2001) 167(8):4560-4565.
150. Xiang R, Silletti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, Pertl U, Gillies SD, Primus FJ, Reisfeld RA: Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res (2001) 7 3 Suppl):856S-864S.
151. Niethammer AG, Primus FJ, Xiang R, Dolman CS, Ruehlmann JM, Ba Y, Gillies SD, Reisfeld RA: An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine (2001) 20 3-4):421-429.
152. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 8(12):1369-1375.
153. Rosenkranz CD, Chiara D, Agorio C, Baz A, Pasetti MF, Schreiber F, Dematteis S, Martinez M, Sztein MB, Chabalgoity JA: Towards new immunotherapies: Targeting recombinant cytokines to the immune system using live attenuated Salmonella. Vaccine (2003) 21(7-8):798-801.
154. Yuhua L, Kunyuan G, Hui C, Yongmei X, Chaoyang S, Xun T, Daming R: Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer (2001) 94(3):438-443.
155. Paglia P, Terrazzini N, Schulze K, Guzman CA, Colombo MP: In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther (2000) 7(20):1725-1730.
156. Urashima M, Suzuki H, Yuza Y, Akiyama M, Ohno N, Eto Y: An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood (2000) 95(4 ):1258-1263.
157. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM: Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther (1996) 3(2):173-178.
158. Theys J, Nuyts S, Landuyt W, Van Mellaert L, Dillen C, Bohringer M, Durre P, Lambin P, Anne J: Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor α. Appl Environ Microbiol (1999) 65 10):4295-4300.
159. Radford KJ, Jackson AM, Wang JH, Vassaux G, Lemoine NR: Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: Presentation of MART1 to CD8+ T cells. Int J Cancer (2003) 105(6):811-819.
160. Hu PQ, Tuma-Warrino RJ, Bryan MA, Mitchell KG, Higgins DE,